tracken
Madrigal Pharmaceuticals, Inc. Aktie News
Neutral
Seeking Alpha
●
2 Tage alt
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral
GlobeNewsWire
●
6 Tage alt
CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, strengthening the company's leadership in sha...
Neutral
The Motley Fool
●
9 Tage alt
The bull case wasn't helped by an analyst's recommendation downgrade. That pundit now feels the biotech's shares only rate a hold.
Positiv
The Motley Fool
●
10 Tage alt
Nektar Therapeutics has a promising lead drug candidate, but there is considerable risk involved. Madrigal Pharmaceuticals is generating strong revenue from a medicine with significant prospects.
Positiv
Seeking Alpha
●
10 Tage alt
Madrigal Pharmaceuticals maintains a "Strong Buy" rating, driven by Rezdiffra's FDA approval for F2-F3 MASH and robust sales momentum. MDGL is expanding Rezdiffra's reach, targeting F4 compensated MASH cirrhosis with the pivotal phase 3 MAESTRO-NASH-OUTCOMES trial; data is expected in 2027. Two-year open-label data show Rezdiffra improves key biomarkers in hard-to-treat F4c MASH cirrhosis patie...
Neutral
GlobeNewsWire
●
28 Tage alt
CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 15, 2025 to 4 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Induc...
Neutral
GlobeNewsWire
●
etwa ein Monat alt
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST.
Positiv
The Motley Fool
●
etwa ein Monat alt
Summit Therapeutics has an incredibly promising cancer candidate in the pipeline. Madrigal Pharmaceuticals made a breakthrough that could drive strong results for years to come.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
